Dysregulated mTOR-dependent signaling in neurodegeneration or carcinogenesis: Implication for alzheimer's disease and brain tumors

Journal of Alzheimer's Disease

Volumn 37, Issue 3, 2013, Pages 495-505

  Wang, Shan ^a   Wu, Jing ^b   Nie, Sheng Dan ^c   Bereczki, Erika ^d   Pei, Jin Jing ^d  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

^c HUNAN NORMAL UNIVERSITY   (China)

^d KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Alzheimer's disease; carcinogenesis; mTOR; neurodegeneration

Indexed keywords

AMYLOID; GLUTAMIC ACID; MAMMALIAN TARGET OF RAPAMYCIN; MICRORNA; TAU PROTEIN;

ALZHEIMER DISEASE; APOPTOSIS; AUTOPHAGY; BRAIN TUMOR; CARCINOGENESIS; CELL TYPE; CENTRAL NERVOUS SYSTEM; DISEASE COURSE; EXCITOTOXICITY; GENE MUTATION; GLIA CELL; HUMAN; HYPOXIA; INFLAMMATION; NERVE DEGENERATION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TAUOPATHY; UPREGULATION;

ALZHEIMER DISEASE; ANIMALS; BRAIN NEOPLASMS; CARCINOGENESIS; HUMANS; MUTATION; NEURODEGENERATIVE DISEASES; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84892739190     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-130641     Document Type: Review

References (118)

1. Amor S, Puentes F, Baker D, van der Valk P (2010) Inflammation in neurodegenerative diseases. Immunology 129, 154-169.
2. Pei JJ, Hugon J (2008) mTOR-dependent signalling in Alzheimer's disease. J Cell Mol Med 12, 2525-2532.
3. Zoncu R, Efeyan A, Sabatini DM (2011) mTOR: From growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 12, 21-35.
4. Wullschleger S, Loewith R, Oppliger W, Hall MN (2005) Molecular organization of target of rapamycin complex 2. J Biol Chem 280, 30697-30704.
5. Kim DH, Sarbassov DD, Ali SM, King JE, Latek RR, Erdjument-Bromage H, Tempst P, Sabatini DM (2002) mTOR interacts with raptortoformanutrient-sensitive complex that signals to the cell growth machinery. Cell 110, 163-175.
6. Sengupta S, Peterson TR, Sabatini DM (2010) Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress. Mol Cell 40, 310-322.
7. Jacinto E, Loewith R, Schmidt A, Lin S, Ruegg MA, Hall A, Hall MN (2004) Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 6, 1122-1128.
8. Sarbassov DD, Ali SM, Kim DH, Guertin DA, Latek RR, Erdjument-Bromage H, Tempst P, Sabatini DM (2004) Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 14, 1296-1302.
9. Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, Bagley AF, Markhard AL, Sabatini DM (2006) Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 22, 159-168.
10. Alayev A, Holz MK (2013) mTOR signaling for biological control and cancer. J Cell Physiol 228, 1658-1664.
11. Li X, Alafuzoff I, Soininen H, Winblad B, Pei JJ (2005) Levels of mTOR and its downstream targets 4E-BP1, eEF2, and eEF2 kinase in relationships with tau in Alzheimer's disease brain. FEBS J 272, 4211-4220.
12. An WL, Cowburn RF, Li L, Braak H, Alafuzoff I, Iqbal K, Iqbal IG, Winblad B, Pei JJ (2003) Up-regulation of phosphorylated/activated p70 S6 kinase and its relationship to neurofibrillary pathology in Alzheimer's disease. Am J Pathol 163, 591-607.
13. Caccamo A, Majumder S, Richardson A, Strong R, Oddo S (2010) Molecular interplay between mammalian target of rapamycin (mTOR), amyloid-beta, and Tau: Effects on cognitive impairments. J Biol Chem 285, 13107-13120.
14. Kato Y, Nishihara H, Yuzawa S, Mohri H, Kanno H, Hatanaka Y, Kimura T, Tanino M, Tanaka S (2012) Immuno-histochemical molecular expression profile of metastatic brain tumor for potent personalized medicine. Brain Tumor Pathol (in press). doi: 10.1007/s10014-012-0124-y
15. Mohan AL, Friedman MD, Ormond DR, Tobias M, Murali R, Jhanwar-Uniyal M (2012) PI3K/mTOR signaling pathways in medulloblastoma. Anticancer Res 32, 3141-3146.
16. Bashir T, Cloninger C, Artinian N, Anderson L, Bernath A, Holmes B, Benavides-Serrato A, Sabha N, Nishimura RN, Guha A, Gera J (2012) Conditional astroglial Rictor over-expression induces malignant glioma in mice. PLoS One 7, e47741.
17. Ismail HM (2012) Overexpression of s6 kinase 1 in brain tumours is associated with induction of hypoxia-responsive genes and predicts patients' survival. J Oncol 2012, 416927.
18. Arcella A, Biagioni F, Antonietta Oliva M, Bucci D, Frati A, Esposito V, Cantore G, Giangaspero F, Fornai F (2013) Rapamycin inhibits the growth of glioblastoma. Brain Res 1495, 37-51.
19. Weingarten MD, Lockwood AH, Hwo SY, Kirschner MW (1975) A protein factor essential for microtubule assembly. Proc Natl Acad Sci USA 72, 1858-1862.
20. Pei JJ, An WL, Zhou XW, Nishimura T, Norberg J, Benedikz E, Gotz J, Winblad B (2006) P70 S6 kinase mediates tau phosphorylation and synthesis. FEBS Lett 580, 107-114.
21. Caccamo A, Magri A, Medina DX, Wisely EV, Lopez-Aranda MF, Silva AJ, Oddo S (2013) mTOR regulates tau phosphorylation and degradation: Implications for Alzheimer's disease and other tauopathies. Aging Cell 12, 370-380.
22. Tang Z, Bereczki E, Zhang H, Wang S, Li C, Ji X, Branca RM, Lehtio J, Guan Z, Filipcik P, Xu S, Winblad B, Pei JJ (2013) Mammalian target of rapamycin (mTor) mediates tau protein dyshomeostasis: Implication for Alzheimer disease. J Biol Chem 288, 15556-15570.
23. de Bont JM, Vanderstichele H, Reddingius RE, Pieters R, van Gool SW (2008) Increased total-Tau levels in cere-brospinal fluid of pediatric hydrocephalus and brain tumor patients. Eur J Paediatr Neurol 12, 334-341.
24. Brat DJ, Gearing M, Goldthwaite PT, Wainer BH, Burger PC (2001) Tau-associated neuropathology in ganglion cell tumours increases with patient age but appears unrelated to ApoE genotype. Neuropathol Appl Neurobiol 27, 197-205.
25. Avrahami L, Farfara D, Shaham-Kol M, Vassar R, Frenkel D, Eldar-Finkelman H (2013) Inhibition of glycogen synthase kinase-3 ameliorates beta-amyloid pathology and restores lysosomal acidification and mammalian target of rapamycin activity in the Alzheimer disease mouse model: In vivo and in vitro studies. J Biol Chem 288, 1295-1306.
26. Yoon SO, Park DJ, Ryu JC, Ozer HG, Tep C, Shin YJ, Lim TH, Pastorino L, Kunwar AJ, Walton JC, Nagahara AH, Lu KP, Nelson RJ, Tuszynski MH, Huang K (2012) JNK3 perpetuates metabolic stress inducedbyAbeta peptides. Neuron 75, 824-837.
27. Li L, Xu B, Zhu Y, Chen L, Sokabe M, Chen L (2010) DHEA prevents Abeta25-35-impaired survival of newborn neurons in the dentate gyrus through a modulation of PI3K-Akt-mTOR signaling. Neuropharmacology 59, 323-333.
28. Chen TJ, Wang DC, Chen SS (2009) Amyloid-beta interrupts the PI3K-Akt-mTOR signaling pathway that could be involved in brain-derived neurotrophic factor-induced Arc expression in rat cortical neurons. J Neurosci Res 87, 2297-2307.
29. Lafay-Chebassier C, Paccalin M, Page G, Barc-Pain S, Perault-Pochat MC, Gil R, Pradier L, Hugon J (2005) mTOR/p70S6k signalling alteration by Abeta exposure as well as in APP-PS1 transgenic models and in patients with Alzheimer's disease. J Neurochem 94, 215-225.
30. Son SM, Song H, Byun J, Park KS, Jang HC, Park YJ, Mook-Jung I (2012) Accumulation of autophagosomes contributes to enhanced amyloidogenic APP processing under insulin-resistant conditions. Autophagy 8, 1842-1844.
31. Son SM, Song H, Byun J, Park KS, Jang HC, Park YJ, Mook-Jung I (2012) Altered APP processing in insulin-resistant conditions is mediated by autophagosome accumulation via the inhibition of mammalian target of rapamycin pathway. Diabetes 61, 3126-3138.
32. Ma T, Hoeffer CA, Capetillo-Zarate E, Yu F, Wong H, Lin MT, Tampellini D, Klann E, Blitzer RD, Gouras GK (2010) Dysregulation of the mTOR pathway mediates impairment of synaptic plasticity in a mouse model of Alzheimer's disease. PLoS One 5, pii: e12845.
33. Lafay-Chebassier C, Perault-Pochat MC, Page G, Rioux Bilan A, Damjanac M, Pain S, Houeto JL, Gil R, Hugon J (2006) The immunosuppressant rapamycin exacerbates neurotoxicity of Abeta peptide. J Neurosci Res 84, 1323-1334.
34. Colella S, Ohgaki H, Ruediger R, Yang F, Nakamura M, Fujisawa H, Kleihues P, Walter G (2001) Reduced expression of the Aalpha subunit of protein phosphatase 2A in human gliomas in the absence of mutations in the Aalpha and Abeta subunit genes. Int J Cancer 93, 798-804.
35. Zhao H, Zhu J, Cui K, Xu X, O'Brien M, Wong KK, Kesari S, Xia W, Wong ST (2009) Bioluminescence imaging reveals inhibition of tumor cell proliferation by Alzheimer's amyloid beta protein. Cancer Cell Int 9, 15.
36. Hochfeld WE, Lee S, Rubinsztein DC (2013) Therapeutic induction of autophagy to modulate neurodegenerative disease progression. Acta Pharmacol Sin 34, 600-604.
37. Cai Z, Zhao B, Li K, Zhang L, Li C, Quazi SH, Tan Y (2012) Mammalian target of rapamycin: A valid therapeutic target through the autophagy pathway for Alzheimer's disease? J Neurosci Res 90, 1105-1118.
38. Oddo S (2012) The role of mTOR signaling in Alzheimer disease. Front Biosci (Schol Ed) 4, 941-952.
39. Buytaert E, Callewaert G, Vandenheede JR, Agostinis P (2006) Deficiencyinapoptoticeffectors Bax and Bak reveals an autophagic cell death pathway initiated by photodamage to the endoplasmic reticulum. Autophagy 2, 238-240.
40. Wirawan E, Vanden Berghe T, Lippens S, Agostinis P, Van-denabeele P (2012) Autophagy: For better or for worse. Cell Res 22, 43-61.
41. Ding WX, Chen X, Yin XM (2012) Tumor cells can evade dependence onautophagy through adaptation. Biochem Bio-phys Res Commun 425, 684-688.
42. Palumbo S, Comincini S (2013) Autophagy and ionizing radiation in tumors: The "survive or not survive" dilemma. J Cell Physiol 228, 1-8.
43. Hu YL, DeLay M, Jahangiri A, Molinaro AM, Rose SD, Carbonell WS, Aghi MK (2012) Hypoxia-induced autophagy promotes tumor cell survival and adaptation to antiangio-genic treatment in glioblastoma. Cancer Res 72, 1773-1783.
44. Jiang H, White EJ, Conrad C, Gomez-Manzano C, Fueyo J (2009) Autophagy pathways in glioblastoma. Methods Enzymol 453, 273-286.
45. Maiese K, Chong ZZ, Shang YC, Wang S (2012) Targeting disease through novel pathways of apoptosis and autophagy. Expert Opin Ther Targets 16, 1203-1214.
46. Woodle ES, Kulkarni S (1998) Programmed cell death. Transplantation 66, 681-691.
47. Weng HY, Hsu MJ, Chen CC, Chen BC, Hong CY, Teng CM, Pan SL, Chiu WT, Lin CH (2013) Denbinobin induces human glioblastoma multiforme cell apoptosis through the IKKalpha-Akt-FKHR signaling cascade. Eur J Pharmacol 698, 103-109.
48. Krakstad C, Chekenya M (2010) Survival signalling and apoptosis resistance in glioblastomas: Opportunities for targeted therapeutics. Mol Cancer 9, 135.
49. Koul N, Sharma V, Dixit D, Ghosh S, Sen E (2010) Bicyclic triterpenoid Iripallidal induces apoptosis and inhibits Akt/mTOR pathway in glioma cells. BMC Cancer 10, 328.
50. Jacinto E, Hall MN (2003) Tor signalling in bugs, brain and brawn. Nat Rev Mol Cell Biol 4, 117-126.
51. Maiese K, Chong ZZ, Shang YC, Wang S (2013) mTOR: On target for novel therapeutic strategies in the nervous system. Trends Mol Med 19, 51-60.
52. Chen L, Xu B, Liu L, Luo Y, Yin J, Zhou H, Chen W, Shen T, Han X, Huang S (2010) Hydrogen peroxide inhibits mTOR signaling by activation of AMPKalpha leading to apoptosis of neuronal cells. Lab Invest 90, 762-773.
53. Huang S, Houghton PJ (2003) Targeting mTOR signaling for cancer therapy. Curr Opin Pharmacol 3, 371-377.
54. Srividya MR, Thota B, Shailaja BC, Arivazhagan A, Then-narasu K, Chandramouli BA, Hegde AS, Santosh V (2011) Homozygous 10q23/PTEN deletion and its impact on outcome in glioblastoma: A prospective translational study on a uniformly treated cohort of adult patients. Neuropathology 31, 376-383.
55. Mueller S, Phillips J, Onar-Thomas A, Romero E, Zheng S, Wiencke JK, McBride SM, Cowdrey C, Prados MD, Weiss WA, Berger MS, Gupta N, Haas-Kogan DA (2012) PTEN promoter methylation and activation of the PI3K/Akt/mTOR pathway in pediatric gliomas and influence on clinical outcome. Neuro Oncol 14, 1146-1152.
56. Waldron JS, Yang I, Han S, Tihan T, Sughrue ME, Mills SA, Pieper RO, Parsa AT (2010) Implications for immunother-apy of tumor-mediated T-cell apoptosis associated with loss of the tumor suppressor PTEN in glioblastoma. J Clin Neu-rosci 17, 1543-1547.
57. Griffin RJ, Moloney A, Kelliher M, Johnston JA, Ravid R, Dockery P, O'Connor R, O'Neill C (2005) Activation of Akt/PKB, increased phosphorylation of Akt substrates and loss and altered distribution of Akt and PTEN are features of Alzheimer's disease pathology. J Neurochem 93, 105-117.
58. Rickle A, Bogdanovic N, Volkmann I, Zhou X, Pei JJ, Win-blad B, Cowburn RF (2006) PTEN levels in Alzheimer's disease medial temporal cortex. Neurochem Int 48, 114-123.
59. Zhang X, Li F, Bulloj A, Zhang YW, Tong G, Zhang Z, Liao FF, Xu H (2006) Tumor-suppressor PTEN affects tau phosphorylation, aggregation, and binding to microtubules. FASEB J 20, 1272-1274.
60. Sonoda Y, Mukai H, Matsuo K, Takahashi M, Ono Y, Maeda K, Akiyama H, Kawamata T (2010) Accumulation of tumor-suppressor PTEN in Alzheimer neurofibrillary tangles. Neurosci Lett 471, 20-24.
61. Chen Z, Chen B, Xu WF, Liu RF, Yang J, Yu CX (2012) Effects of PTEN inhibition on regulation of tau phosphory-lation in an okadaic acid-induced neurodegeneration model. Int J Dev Neurosci 30, 411-419.
62. Zha X, Hu Z, He S, Wang F, Shen H, Zhang H (2011) TSC1/TSC2 inactivation inhibits AKT through mTORC1-dependent up-regulation of STAT3-PTEN cascade. Cancer Lett 313, 211-217.
63. Guo Y, Kwiatkowski DJ (2013) Equivalent benefit of rapamycin and a potent mTOR ATP-competitive inhibitor, MLN0128 (INK128), in a mouse model of tuberous sclerosis. Mol Cancer Res 11, 467-473.
64. Androsova LV, Mikhailova NM, Zozulia SA, Dupin AM, Rassadina GA, Lavrent'eva NV, Kliushnik TP (2013) [Inflammatory markers in Alzheimer's disease and vascular dementia.]. Zh Nevrol Psikhiatr Im S S Korsakova 113, 49-53.
65. Berindan-Neagoe I, Chiorean R, Braicu C, Florian IS, Leucuta D, Crisan D, Cocis A, Balacescu O, Irimie A (2012) Quantitative mRNA expression of genes involved in angiogenesis, coagulation and inflammation in multiforme glioblastoma tumoral tissue versus peritumoral brain tissue: Lack of correlation with clinical data. Eur Cytokine Netw 23, 45-55.
66. Liebrich M, Guo LH, Schluesener HJ, Schwab JM, Dietz K, Will BE, Meyermann R (2007) Expression of interleukin-16 by tumor-associated macrophages/activated microglia in high-grade astrocytic brain tumors. Arch Immunol TherExp (Warsz) 55, 41-47.
67. Degos V, Peineau S, Nijboer C, Kaindl AM, Sigaut S, Favrais G, Plaisant F, Teissier N, Gouadon E, Lombet A, Saliba E, Collingridge GL, Maze M, Nicoletti F, Heijnen C, Mantz J, Kavelaars A, Gressens P (2013) G protein-coupled receptor kinase 2 and group I metabotropic glutamate receptors mediate inflammation-induced sensitization to excitotoxic neurodegeneration. Ann Neurol 73, 667-678.
68. Ghosh S, Wu MD, Shaftel SS, Kyrkanides S, Laferla FM, Olschowka JA, O'Banion MK (2013) Sustained interleukin-1beta overexpression exacerbates tau pathology despite reduced amyloid burden in an Alzheimer's mouse model. J Neurosci 33, 5053-5064.
69. Sen E (2011) Targeting inflammation-induced transcription factor activation: An open frontier for glioma therapy. Drug Discov Today 16, 1044-1051.
70. Lopategui Cabezas I, Herrera Batista A, Penton Rol G (2012) The role of glial cells in Alzheimer's disease: Potential therapeutic implications. Neurologia (in press). doi:10.1016/j.nrl.2012.10.006
71. Lee DF, Kuo HP, Chen CT, Hsu JM, Chou CK, Wei Y, Sun HL, Li LY, Ping B, Huang WC, He X, Hung JY, Lai CC, Ding Q, Su JL, Yang JY, Sahin AA, Hortobagyi GN, Tsai FJ, Tsai CH, Hung MC (2007) IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway. Cell 130, 440-455.
72. Zhang W, Wang LZ, Yu JT, Chi ZF, Tan L (2012) Increased expressions of TLR2 and TLR4 on peripheral blood mononuclear cells from patients with Alzheimer's disease. J Neurol Sci 315, 67-71.
73. Landreth GE, Reed-Geaghan EG (2009) Toll-like receptors in Alzheimer's disease. Curr Top Microbiol Immunol 336, 137-153.
74. Tewari R, Choudhury SR, Ghosh S, Mehta VS, Sen E (2012) Involvement of TNFalpha-induced TLR4-NF-kappaB and TLR4-HIF-1alpha feed-forward loops in the regulation of inflammatory responses in glioma. J Mol Med (Berl) 90, 67-80.
75. Zhao J, Benakanakere MR, Hosur KB, Galicia JC, Martin M, Kinane DF (2010) Mammalian target of rapamycin (mTOR) regulates TLR3 induced cytokines in human oral keratinocytes. Mol Immunol 48, 294-304.
76. Lorne E, Zhao X, Zmijewski JW, Liu G, Park YJ, Tsuruta Y, Abraham E (2009) Participation of mammalian target of rapamycin complex 1 in Toll-like receptor 2-and 4-induced neutrophil activation and acute lung injury. Am J Respir Cell Mol Biol 41, 237-245.
77. Gao L, Tian S, Gao H, Xu Y (2013) Hypoxia increases Afj-induced tau phosphorylation by calpain and promotes behavioral consequences in AD transgenic mice. J Mol Neurosci. doi: 10.1007/s12031-013-9966-y
78. Zhang X, Li L, Zhang X, Xie W, Li L, Yang D, Heng X, Du Y, Doody RS, Le W (2013) Prenatal hypoxia may aggravate the cognitive impairment and Alzheimer's disease neuropathology in APPSwe/PS1A246E transgenic mice. Neurobiol Aging 34, 663-678.
79. Mongiardi MP (2012) Angiogenesis and hypoxia in glioblastoma: A focus on cancer stem cells. CNS Neurol Disord Drug Targets 11, 878-883.
80. Desmond DW, Moroney JT, Sano M, Stern Y (2002) Incidence of dementia after ischemic stroke: Results of a longitudinal study. Stroke 33, 2254-2260.
81. Fleisher AS, Podraza KM, Bangen KJ, Taylor C, Sherzai A, Sidhar K, Liu TT, Dale AM, Buxton RB (2009) Cere-bral perfusion and oxygenation differences in Alzheimer's disease risk. Neurobiol Aging 30, 1737-1748.
82. Erpolat OP, Gocun PU, Akmansu M, Ozgun G, Akyol G (2013) Hypoxia-related molecules HIF-1alpha, CA9, and osteopontin: Predictors of survival in patients with high-grade glioma. Strahlenther Onkol 189, 147-154.
83. Liu Y, Liu F, Iqbal K, Grundke-Iqbal I, Gong CX (2008) Decreased glucose transporters correlate to abnormal hyper-phosphorylation of tauinAlzheimer disease. FEBS Lett582, 359-364.
84. Reszec J, Rutkowski R, Chyczewski L (2013) The expres-sionof Hypoxia-Inducible Factor-1 inprimary brain tumors. Int J Neurosci. doi:10.3109/00207454.2013.789874
85. Kaynar MY, Sanus GZ, Hnimoglu H, Kacira T, Kemerdere R, Atukeren P, Gumustas K, Canbaz B, Tanriverdi T (2008) Expression of hypoxia inducible factor-1alpha in tumors of patients with glioblastoma multiforme and transitional meningioma. J Clin Neurosci 15, 1036-1042.
86. Zhang Z, Yan J, Chang Y, ShiDu Yan S, Shi H (2011) Hypoxia inducible factor-1 as a target for neurodegenerative diseases. Curr Med Chem 18, 4335-4343.
87. Land SC, Tee AR (2007) Hypoxia-inducible factor 1alpha is regulated by the mammalian target of rapamycin (mTOR) via an mTOR signaling motif. J Biol Chem 282, 20534-20543.
88. Agani F, Jiang BH (2013) Oxygen-independent regulation of HIF-1: Novel involvement of PI3K/AKT/mTOR pathway in cancer. Curr Cancer Drug Targets 13, 245-251.
89. Karar J, Maity A (2011) PI3K/AKT/mTOR pathway in angiogenesis. Front Mol Neurosci 4, 51.
90. Liu L, Cash TP, Jones RG, Keith B, Thompson CB, Simon MC (2006) Hypoxia-induced energy stress regulates mRNA translation and cell growth. Mol Cell 21, 521-531.
91. Blagosklonny MV (2013) Hypoxia, MTOR and autophagy: Convergingonsenescenceorquiescence. Autophagy 9, 260-262.
92. Ong WY, Tanaka K, Dawe GS, Ittner LM, Farooqui AA (2013) Slow excitotoxicity in Alzheimer's disease. J Alzheimers Dis 35, 643-668.
93. Nilsen LH, Rae C, Ittner LM, Gotz J, Sonnewald U (2013) Glutamate metabolism is impaired in transgenic mice with tau hyperphosphorylation. J Cereb Blood Flow Metab 33, 684-691.
94. de Groot J, Sontheimer H (2011) Glutamate and the biology of gliomas. Glia 59, 1181-1189.
95. Zepeda RC, Barrera I, Castelan F, Suarez-Pozos E, Melgarejo Y, Gonzalez-Mejia E, Hernandez-Kelly LC, Lopez-Bayghen E, Aguilera J, Ortega A (2009) Glutamate-dependent phosphorylation of the mammalian target of rapamycin (mTOR) in Bergmann glial cells. Neurochem Int 55, 282-287.
96. Lopez-Colome AM, Martinez-Lozada Z, Guillem AM, Lopez E, Ortega A (2012) Glutamate transporter-dependent mTOR phosphorylation in Muller glia cells. ASN Neuro 4, e00095.
97. Ru W, Peng Y, Zhong L, Tang SJ (2012) A role of the mammalian target of rapamycin (mTOR) in glutamate-induced down-regulation of tuberous sclerosis complex proteins 2 (TSC2). J Mol Neurosci 47, 340-345.
98. Ittner LM, Gotz J (2011) Amyloid-beta and tau-a toxic pas de deux in Alzheimer's disease. Nat Rev Neurosci 12, 65-72.
99. Ittner LM, Ke YD, Delerue F, Bi M, Gladbach A, van Eersel J, Wolfing H, Chieng BC, Christie MJ, Napier IA, Eckert A, Staufenbiel M, Hardeman E, Gotz J (2010) Dendritic func-tion of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. Cell 142, 387-397.
100. Guo H, Ingolia NT, Weissman JS, Bartel DP (2010) Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature 466, 835-840.
101. Satoh J (2012) Molecular network analysis of human microRNA targetome: From cancerstoAlzheimer's disease. Bio Data Min 5, 17.
102. Tumaneng K, Schlegelmilch K, Russell RC, Yimlamai D, Basnet H, Mahadevan N, Fitamant J, Bardeesy N, Camargo FD, Guan KL (2012) YAP mediates crosstalk between the Hippo and PI (3) K-TOR pathways by suppressing PTEN via miR-29. Nat Cell Biol 14, 1322-1329.
103. Wang WX, Huang Q, Hu Y, Stromberg AJ, Nelson PT (2011) Patternsofmicro RNA expressioninnormal and early Alzheimer's disease human temporal cortex: White matter versus gray matter. Acta Neuropathol 121, 193-205.
104. Xu H, Cheung IY, Guo HF, Cheung NK (2009) MicroRNA miR-29 modulates expression of immunoin-hibitory molecule B7-H3: Potential implications for immune based therapy of human solid tumors. Cancer Res 69, 6275-6281.
105. Wang X, Liu P, Zhu H, Xu Y, Ma C, Dai X, Huang L, Liu Y, Zhang L, Qin C (2009) miR-34a, a microRNA up-regulated in a double transgenic mouse model of Alzheimer's disease, inhibits bcl2 translation. Brain Res Bull 80, 268-273.
106. Gao H, Zhao H, Xiang W (2013) Expression level of human miR-34a correlates with glioma grade and prognosis. J Neu-rooncol 113, 221-228.
107. Silber J, Jacobsen A, Ozawa T, Harinath G, Pedraza A, Sander C, Holland EC, Huse JT (2012) miR-34a repression in proneural malignant gliomas upregulates expression of its target PDGFRA and promotes tumorigenesis. PLoS One 7, e33844.
108. Li J, Pandey V, Kessler T, Lehrach H, Wierling C (2012) Modeling of miRNA and drug action in the EGFR signaling pathway. PLoS One 7, e30140.
109. Helton KJ, Weeks JK, Phillips NS, Zou P, Kun LE, Khan RB, Gajjar A, Fouladi M, Broniscer A, Boop F, Li CS, Ogg RJ (2008) Diffusion tensor imaging of brainstem tumors: Axonal degeneration of motor and sensory tracts. J Neuro-surg Pediatr 1, 270-276.
110. Lee SG, Kim K, Kegelman TP, Dash R, Das SK, Choi JK, Emdad L, Howlett EL, Jeon HY, Su ZZ, Yoo BK, Sarkar D, Kim SH, Kang DC, Fisher PB (2011) Oncogene AEG-1 promotes glioma-induced neurodegeneration by increasing glutamate excitotoxicity. Cancer Res 71, 6514-6523.
111. Moller H, Mellemkjaer L, McLaughlin JK, Olsen JH (1995) Occurrence of different cancers in patients with Parkinson's disease. BMJ 310, 1500-1501.
112. Vanacore N, Spila-Alegiani S, Raschetti R, Meco G (1999) Mortality cancer riskinparkinsonian patients:Apopulation-based study. Neurology 52, 395-398.
113. Driver JA, Logroscino G, Buring JE, Gaziano JM, Kurth T (2007) A prospective cohort study of cancer incidence following the diagnosis of Parkinson's disease. Cancer Epidemiol Biomarkers Prev 16, 1260-1265.
114. Jansson B, Jankovic J (1985) Low cancer rates among patients with Parkinson's disease. Ann Neurol 17, 505-509.
115. Roe CM, Fitzpatrick AL, Xiong C, Sieh W, Kuller L, Miller JP, Williams MM, Kopan R, Behrens MI, Morris JC (2010) Cancer linked to Alzheimer disease but not vascular dementia. Neurology 74, 106-112.
116. Driver JA, Lu KP (2010) Pin1: A new genetic link between Alzheimer's disease, cancer and aging. Curr Aging Sci 3, 158-165.
117. Lu KP (2004) Pinning down cell signaling, cancer and Alzheimer's disease. Trends Biochem Sci 29, 200-209.
118. Lam PB, Burga LN, Wu BP, Hofstatter EW, Lu KP, Wulf GM (2008) Prolyl isomerase Pin1 is highly expressed in Her2-positive breast cancer and regulates erbB2 protein stability. Mol Cancer 7, 91.